investigating the effect of dexmedetomidine and remifentanil on Postoperative nausea and vomiting after laparoscopic bariatric surgery.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160903029656N2

Enrollment

150

Registered

2019-10-01

Start date

2018-01-21

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post operative nausea and vomiting after bariatric surgery. Obesity due to excess calories

Interventions

Intervention 1: Intervention group: Dexmedetomedine (alpha 2 agonist) infused at a rate of 1 µg / kg body weight per hour during maintenance of anesthesia (60 to 90 minutes), vial 200 µg Precedex mad

Eligibility

Sex/Gender

Female

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: female 18-50 y undergoing Bariatric Surgery

Exclusion criteria

Exclusion criteria: Smoking having motion sickness having surgical complications having the experience of an operation with a duration of one and a half hours or more

Design outcomes

Primary

Measure	Time frame
Prevalence of post operative nausea and vomiting after laparoscopic bariatric surgery. Timepoint: Evaluation of nausea and vomiting at 2, 4, 6, 12 and 24 hours after surgery. Method of measurement: Completion of checklists based on patient reports.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDelavar Parvin

Shahed University

dr.pdelavar@gmail.com+98 21 8895 6905

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026